Article Text

other Versions

PDF
Scleroderma Lung Study (SLS): Differences in the presentation and course of patients with limited versus diffuse systemic sclerosis
  1. Philip J Clements (pclements{at}mednet.ucla.edu)
  1. University of California Los Angeles, United States
    1. Michael D Roth (mroth{at}mednet.ucla.edu)
    1. University of California Los Angeles, United States
      1. Robert Elashoff (relashoff{at}biomath.medsch.ucla.edu)
      1. University of California Los Angeles, United States
        1. Donald P Tashkin (dtashkin{at}mednet.ucla.edu)
        1. University of California Los Angeles, United States
          1. Jonathan Goldin (jgoldin{at}mednet.ucla.edu)
          1. University of California Los Angeles, United States
            1. Richard M Silver (silverr{at}musc.edu)
            1. Medical School of South Carolina, United States
              1. Mildred Sterz (msterz{at}mednet.ucla.edu)
              1. University of California Los Angeles, United States
                1. James R Seibold (jseibold{at}umich.edu)
                1. University of Michigan, United States
                  1. Dean Schraufnagel (schrauf{at}uic.edu)
                  1. University of Illinois, Chicago, United States
                    1. Robert W Simms (rsimms{at}medicine.bu.edu)
                    1. Boston University, United States
                      1. Marcy Bolster (bolsterm{at}musc.edu)
                      1. Medical School of South Carolina, United States
                        1. Robert A Wise (rwise{at}welch.jhu.edu)
                        1. Johns Hopkins, United States
                          1. Virginia Steen (steenv{at}gunet.georgetown.edu)
                          1. Georgetown University, United States
                            1. Maureen D Mayes (maureen.d.mayes{at}uth.tmc.edu)
                            1. University of Texas, United States
                              1. Kari Connolly (connolly{at}derm.ucsf.edu)
                              1. University of California San Francisco, United States
                                1. Mark Metersky (metersky{at}nso.uchc.edu)
                                1. University of Connecticut, United States
                                  1. Daniel E Furst (defurst{at}mednet.ucla.edu)
                                  1. University of California Los Angeles, United States

                                    Abstract

                                    Objectives: Pulmonary fibrosis is a leading cause of death in systemic sclerosis (SSc). This report examines the differences at baseline and over 12 months between patients with limited versus diffuse cutaneous SSc who participated in the Scleroderma Lung Study.

                                    Methods: SSc patients (64 limited; 94 diffuse) exhibiting dyspnea on exertion, restrictive pulmonary function and evidence of alveolitis on bronchoalveolar lavage and/or high-resolution computed tomography (HRCT) were randomized to receive cyclophosphamide (CYC) or placebo and serially evaluated over 12 months.

                                    Results: Baseline measures of alveolitis, dyspnea and pulmonary function were similar in limited and diffuse SSc. However, differences were noted with respect to HRCT-scored fibrosis (worse in limited SSc), and to functional activity, quality of life, skin and musculoskeletal manifestations (worse in diffuse SSc) (p< 0.05). When adjusted for the baseline level of fibrosis, both groups responded similarly to CYC with regard to lung function and dyspnea (p<0.05). Cyclophosphamide was also associated with more improvement in skin score in the diffuse disease group more than in the limited disease group (p<0.05).

                                    Conclusions: After adjusting for the severity of fibrosis at baseline, CYC slowed the decline of lung volumes and improved dyspnea equally in the limited and the diffuse SSc groups. On the other hand diffuse SSc patients responded better than limited patients with respect to improvements in skin thickening.

                                    • cyclophosphamide
                                    • diffuse cutaneous scleroderma
                                    • limited cutaneous scleroderma
                                    • scleroderma
                                    • systemic sclerosis

                                    Statistics from Altmetric.com

                                    Request permissions

                                    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.